A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Natarajan, Rama, Ph.D, F.A.H.A, F.A.S.N. Research Bookmark and Share

Rama Natarajan, Ph.D, F.A.H.A, F.A.S.N. Research

The major focus of our research is to determine the cellular and molecular mechanisms that play key roles in the development of diabetic vascular complications. We use genomic, transcriptomic and epigenomic approaches in cell culture, animal and clinical models to examine our hypothesis that accelerated vascular complications result from enhanced vascular and renal cell growth, and also monocyte activation due to altered expression of inflammatory cytokines, chemokines and lipids under diabetic conditions.
 
We are actively evaluating molecular mechanisms involved in the expression of pathological genes under diabetic conditions and in promoting metabolic memory. We have demonstrated the role of specific chromatin histone posttranslational modifications in the epigenetic regulation of inflammatory genes. We use epigenomic profiling approaches to map histone modifications, DNA methylation and binding of chromatin factors at diabetes-regulated genes with techniques such as Chromatin immunoprecipitation (ChIP) assays, ChIP-linked to microarrays, and ChIP-Sequencing. We have uncovered key epigenetic alterations under diabetic conditions in vitro, in vivo in diabetic mice, and in cells from diabetic patients, and shown relevance to the phenomenon of metabolic memory.
 
Another active area is the evaluation of specific microRNAs in regulating the expression of inflammatory and fibrotic genes under diabetic conditions. We are examining various mechanisms of microRNA regulation, performing expression profiling using RNA-sequencing, and studying how key microRNAs co-operate with each other in a circuit to amplify the effects of growth factors under diabetic conditions. To test the functional significance in the kidney, we are generating microRNA knockout mice and also evaluating novel modified inhibitors of specific microRNAs (antagomirs) on the progression of diabetic kidney disease in mouse models.
 

Rama Natarajan, Ph.D., Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rama Natarajan, Ph.D., F.A.H.A, F.A.S.N.
National Office Products Endowed Professor
626-256-HOPE (4673), ext. 62289
 
Marpadga A. Reddy, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63671
 
Feng Miao, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 65575
 
Mitsuo Kato, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63996
 
Kirti Bhatt, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65811
 
Nancy Castro, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64690
 
Ye Jia, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62289
 
Amy Leung, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62278
 
Jung-tak Park, M.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64809
 
Hang Yuan, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65817
 
Supriya Deschpande
Graduate Student
626-256-HOPE (4673), ext. 65835
 
Wen Jin
Graduate Student
626-256-HOPE (4673), ext. 65823
 
Linda Lanting, B.S.
Research Associate
626-256-HOPE (4673), ext. 64692
 
Mei Wang, M.S.
Research Associate
626-256-HOPE (4673), ext. 64676
 
Lingxiao Zhang, M.S.
Research Associate
626-256-HOPE (4673), ext. 65571
 
Nancy (Zhuo) Chen
Bioinformatics Specialist
656-256-HOPE (4673), ext. 65058
 

Natarajan, Rama, Ph.D, F.A.H.A, F.A.S.N. Research

Rama Natarajan, Ph.D, F.A.H.A, F.A.S.N. Research

The major focus of our research is to determine the cellular and molecular mechanisms that play key roles in the development of diabetic vascular complications. We use genomic, transcriptomic and epigenomic approaches in cell culture, animal and clinical models to examine our hypothesis that accelerated vascular complications result from enhanced vascular and renal cell growth, and also monocyte activation due to altered expression of inflammatory cytokines, chemokines and lipids under diabetic conditions.
 
We are actively evaluating molecular mechanisms involved in the expression of pathological genes under diabetic conditions and in promoting metabolic memory. We have demonstrated the role of specific chromatin histone posttranslational modifications in the epigenetic regulation of inflammatory genes. We use epigenomic profiling approaches to map histone modifications, DNA methylation and binding of chromatin factors at diabetes-regulated genes with techniques such as Chromatin immunoprecipitation (ChIP) assays, ChIP-linked to microarrays, and ChIP-Sequencing. We have uncovered key epigenetic alterations under diabetic conditions in vitro, in vivo in diabetic mice, and in cells from diabetic patients, and shown relevance to the phenomenon of metabolic memory.
 
Another active area is the evaluation of specific microRNAs in regulating the expression of inflammatory and fibrotic genes under diabetic conditions. We are examining various mechanisms of microRNA regulation, performing expression profiling using RNA-sequencing, and studying how key microRNAs co-operate with each other in a circuit to amplify the effects of growth factors under diabetic conditions. To test the functional significance in the kidney, we are generating microRNA knockout mice and also evaluating novel modified inhibitors of specific microRNAs (antagomirs) on the progression of diabetic kidney disease in mouse models.
 

Lab Members

Rama Natarajan, Ph.D., Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rama Natarajan, Ph.D., F.A.H.A, F.A.S.N.
National Office Products Endowed Professor
626-256-HOPE (4673), ext. 62289
 
Marpadga A. Reddy, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63671
 
Feng Miao, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 65575
 
Mitsuo Kato, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63996
 
Kirti Bhatt, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65811
 
Nancy Castro, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64690
 
Ye Jia, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62289
 
Amy Leung, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62278
 
Jung-tak Park, M.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64809
 
Hang Yuan, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65817
 
Supriya Deschpande
Graduate Student
626-256-HOPE (4673), ext. 65835
 
Wen Jin
Graduate Student
626-256-HOPE (4673), ext. 65823
 
Linda Lanting, B.S.
Research Associate
626-256-HOPE (4673), ext. 64692
 
Mei Wang, M.S.
Research Associate
626-256-HOPE (4673), ext. 64676
 
Lingxiao Zhang, M.S.
Research Associate
626-256-HOPE (4673), ext. 65571
 
Nancy (Zhuo) Chen
Bioinformatics Specialist
656-256-HOPE (4673), ext. 65058
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Beyond the pink ribbons, special product fundraisers, and the pastel sea of color that marks October, Breast Cancer Awareness Month offers a reason to celebrate and to reflect. More than 2.8 million breast cancer survivors live in the U.S. They are survivors of the second most-common cancer in women, behind ski...
  • Gliomas, a type of tumor that grows in the brain, are very difficult to treat successfully due to their complex nature. That might not always be the case. First some background: The most aggressive and common type of primary brain tumor in adults is glioblastoma. Although the brain tumor mass can often be remov...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. The result is rashes and, sometimes, tumors, which can be mistaken for other dermatological conditions. In a smal...
  • Weighing your breast cancer risk? One study suggests a measure to consider is skirt size. A British study suggests that for each increase in skirt size every 10 years after age 25, the five-year risk of developing breast cancer postmenopause increases from one in 61 to one in 51 – a 77 percent increase in risk....
  • Runners prize medals for 5Ks and marathons. Becky Stokes has a medal she cherishes from a very different kind of race: the marathon of treatments necessary to beat her aggressive triple-negative breast cancer. Just a week ago, she completed her last radiation treatment, and danced in the hospital with the staff...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. Darakjian’s s...
  • The environment plays a role in causing cancer – this much we know. But scientists are still trying to understand what that role is, what environmental factors are in play and how precisely those factors are linked to cancer. Now City of Hope researchers have unlocked a clue as to how one carcinogen triggers ca...
  • Jonathan Yamzon, M.D., assistant clinical professor of surgery in the Division of Urology and Urologic Oncology, explains his approach to what’s known as “active surveillance” of men with prostate cancer. Patients need to be educated about their treatment options, he writes. Active surveillanc...
  • For most prostate cancer patients, surgery or radiation therapy is the initial and primary treatment against the disease. But some patients can benefit from chemotherapy and hormone therapy too, especially if there are signs of a relapse or if the cancer has spread beyond the prostate gland. Here, Cy Stein, M.D...
  • Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before. The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital an...
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...